Some experts, however, argue that substitution is not always in the best interest of the patient and can in fact have a negative impact on outcomes – especially in those treated with narrow therapeutic index drugs (NTIDs) also referred to as critical dose drugs.1

According to the World Health Organization approval of a generic is based on the demonstration of interchangeability or therapeutic equivalence to the innovator through bioequivalence studies

Please sign in to read more